Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | DIS-CLL |
|---|---|
| Type | Disease |
| Aliases | CLLSLLХЛЛХронічна лімфоцитарна лейкемія / Дрібноклітинна лімфоцитарна лімфома |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-EHA-WORKUP-2024 SRC-NCCN-BCELL-2025 |
Informational support. All recommendations must be verified by a qualified oncologist. Engineering checks are not clinical validation or treatment approval.
| icd_o_3_morphology | 9823/3 |
|---|---|
| icd_o_3_topography | [] |
| icd_10 | C91.1 |
| who_classification | Mature B-cell leukemias — CLL/SLL per WHO 5th ed. |
Notes
CLL = bone marrow + blood disease (≥5K monoclonal B-cells); SLL = same biology, lymph-node-predominant. Treated identically. iwCLL criteria for treatment indication: progressive cytopenia, symptomatic splenomegaly/lymphadenopathy, B-symptoms, autoimmune cytopenia not responsive to steroids, lymphocyte doubling time <6 mo. Asymptomatic CLL = active surveillance regardless of stage.
Used By
Actionability
BMA-ATM-LOSS-CLL- ATM loss in CLL (del(11q) or somatic mutation): historically poor-prognostic with chemoim...BMA-BCL2-EXPRESSION-CLL- CLL universally expresses BCL2 (no rearrangement needed; driven by miR-15/16 deletion at...BMA-BRAF-V600E-CLL- BRAF V600E in CLL is very rare (~1-3%); does not change standard management (BTKi or vene...BMA-IGHV-UNMUTATED-CLL- IGHV mutational status is a fundamental CLL risk stratifier and treatment-selection bioma...BMA-NOTCH1-ACTIVATING-CLL- NOTCH1 activating mutations (~10-15% of CLL) — adverse prognostic; reduced response to an...BMA-TP53-MUT-CLL- TP53-mut CLL contraindicates chemoimmunotherapy (FCR/BR). BTKi (acalabrutinib, zanubrutin...BMA-TP53-R175H-CLL- TP53 hotspot R175H in CLL — DNA-binding domain dominant-negative variant. Same therapeuti...BMA-TP53-R248Q-CLL- TP53 hotspot R248Q in CLL — DNA-binding domain dominant-negative variant. Same therapeuti...BMA-TP53-R273H-CLL- TP53 hotspot R273H in CLL — DNA-binding domain dominant-negative variant. Same therapeuti...BMA-TP53-R282W-CLL- TP53 hotspot R282W in CLL — DNA-binding domain dominant-negative variant. Same therapeuti...
Algorithms
ALGO-CLL-1L- ALGO-CLL-1LALGO-CLL-2L- ALGO-CLL-2L
Disease
Indication
IND-CLL-1L-AVO- IND-CLL-1L-AVOIND-CLL-1L-BTKI- IND-CLL-1L-BTKIIND-CLL-1L-VENO- IND-CLL-1L-VENOIND-CLL-1L-ZANUBRUTINIB- IND-CLL-1L-ZANUBRUTINIBIND-CLL-2L-VENR-MURANO- IND-CLL-2L-VENR-MURANOIND-CLL-3L-LISOCEL- IND-CLL-3L-LISOCELIND-CLL-3L-PIRTOBRUTINIB- IND-CLL-3L-PIRTOBRUTINIBIND-CLL-ELDERLY-O-CHL- IND-CLL-ELDERLY-O-CHL
Questionnaires
QUEST-CLL-1L- Chronic Lymphocytic Leukemia / SLL — first line
Red flag
RF-BINET-A- CLL/SLL with Binet stage A — lymphocytosis with <3 involved lymphoid areas, no anemia, no...RF-BINET-B-C- CLL/SLL with Binet stage B (≥3 lymphoid areas, no cytopenia) or C (Hb <10 OR platelets <1...RF-CLL-FRAILTY-AGE- Frailty profile influencing CLL regimen selection: ECOG ≥3, OR (age ≥75 with G8 ≤14), OR...RF-CLL-HIGH-RISK- CLL with high-risk genetics: TP53 mutation OR del(17p) OR IGHV-unmutated OR complex karyo...RF-CLL-INFECTION-SCREENING- Active or latent infection requiring resolution / prophylaxis before initiating CLL thera...RF-CLL-ORGAN-DYSFUNCTION- Baseline organ dysfunction precluding standard CLL regimens: CrCl <30 (venetoclax / acala...RF-CLL-POST-BTKI-C481-ACTIONABLE- CLL with acquired BTK C481S (rarely C481R/F/Y) mutation after progression on covalent BTK...RF-CLL-TP53-DELETION-ACTIONABLE- CLL with del(17p) by FISH AND/OR TP53 mutation by NGS — ~5-10% at diagnosis, rising to ~3...RF-CLL-TRANSFORMATION-PROGRESSION- CLL with clinical / biochemical features concerning for Richter transformation (to DLBCL...RF-CLL-VEN-RESISTANT-ACTIONABLE- CLL progression on venetoclax — either acquired BCL2 G101V (or rarer D103Y, A113G, R107_R...RF-RAI-HIGH- CLL/SLL with Rai stage III-IV (anemia Hb <11 g/dL or thrombocytopenia plt <100K from CLL...RF-RAI-LOW- CLL/SLL with Rai stage 0 (lymphocytosis only, no nodes / spleen / cytopenia) — watch-and-...RF-RICHTER-TRANSFORMATION- Richter transformation: histologically confirmed transformation of CLL/SLL to aggressive...
Sources
SRC-ASCEND-GHIA-2020- ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or...SRC-BRUIN-MATO-2021- Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 studySRC-CLL14-FISCHER-2019- Venetoclax and Obinutuzumab in Patients with CLL and Coexisting ConditionsSRC-ELEVATE-TN-SHARMAN-2020- Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treat...SRC-ESMO-CLL-2024- ESMO Clinical Practice Guideline on Chronic Lymphocytic LeukaemiaSRC-MOZ-UA-CLL-2022- Уніфікований клінічний протокол первинної та спеціалізованої медичної допомоги: Хронічний...SRC-MURANO-SEYMOUR-2018- Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia